Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients and Its Relation to Multi-Drug Therapy: Randomized Clinical Trial

What this Trial Is About

Mycobacterium leprae is a slow-growing bacterium that causes leprosy, which can take two to ten years to develop after infection. The bacteria mainly affect peripheral nerves, potentially causing tissue damage, painless burns, ulcers, and loss of protective sensation. This trial examines the role of Rab 32 gene polymorphisms as a possible prognostic factor in leprosy patients while evaluating the effects of standard multi-drug therapy. Participants with leprosy will receive a combination of dapsone, clofazimine, and rifampicin as per World Health Organization guidelines. About 40 patients will be treated with this multi-drug therapy, and blood samples will be collected after three months to study the Rab 32 gene's role. Additionally, around 10 healthy individuals will provide blood samples for comparison, with no treatments administered to them. During the study, participants will undergo assessments including venous blood collection to analyze the Rab 32 gene and monitor treatment impact. Researchers will evaluate treatment outcomes over six months, tracking the effectiveness of the multi-drug therapy. This study aims to better understand genetic factors affecting leprosy prognosis and treatment responses, with safety monitored throughout the trial period.

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients